Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Gains from Investment Securities (2020 - 2022)

Atea Pharmaceuticals has reported Gains from Investment Securities over the past 3 years, most recently at $182350.0 for Q3 2022.

  • Quarterly results put Gains from Investment Securities at $182350.0 for Q3 2022, down 37.66% from a year ago — trailing twelve months through Sep 2022 was $182350.0 (down 37.66% YoY), and the annual figure for FY2025 was $485000.0, changed.
  • Gains from Investment Securities for Q3 2022 was $182350.0 at Atea Pharmaceuticals, down from $724970.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for AVIR hit a ceiling of $10.5 million in Q4 2021 and a floor of $182350.0 in Q3 2022.
  • Median Gains from Investment Securities over the past 3 years was $2.2 million (2021), compared with a mean of $2.6 million.
  • Peak annual rise in Gains from Investment Securities hit 1000.62% in 2021, while the deepest fall reached 90.61% in 2021.
  • Atea Pharmaceuticals' Gains from Investment Securities stood at $3.1 million in 2020, then soared by 237.62% to $10.5 million in 2021, then crashed by 98.27% to $182350.0 in 2022.
  • The last three reported values for Gains from Investment Securities were $182350.0 (Q3 2022), $724970.0 (Q2 2022), and $2.9 million (Q1 2022) per Business Quant data.